

focus




HIV/AIDS
Tuberculosis
Malaria



A Fight for Life

AIDS, tuberculosis and malaria are killing more than 6 million people each year. Facilitating access to effective, yet affordable drugs and medical devices remains a major international concern.



Committed focus

Recent years have seen international organisations launch a number of novel initiatives and comprehensive programmes designed to more effectively fight HIV/AIDS, TB and malaria.

As a consequence, the demand for effective and affordable HIV/AIDS, TB and malaria products is rising, and Missionpharma is committed to making these products physically and financially available to economically disadvantaged populations.

Complete procurement solutions

Years of solid experience and established know-how allow Missionpharma to provide complete procurement solutions to its customers. Our fully integrated Supply Chain Management System affords us full control over all stages of the procurement process, which covers:

Prequalification of manufacturers to ensure that all products meet current safety, efficacy and quality requirements.

Purchase of the right product at the right price.

Storage and Distribution of products from one of our warehouses to the final recipient.



The following provides examples of the comprehensive international initiatives and programmes launched to fight HIV/AIDS, TB and malaria:

WTO consensus on the issue of access to medicines by countries with little or insufficient pharmaceutical production capacity.

WHO prequalification programme facilitating access to drugs of acceptable quality.

WHO commitment to "3 by 5", providing life-saving antiretroviral (ARV) treatment to three million people in developing countries by the end of 2005.

Global Fund (GF) initiative to disburse additional resources contributing to the reduction of illness and death caused by HIV/AIDS, TB and malaria.

Global Drug Facility (GDF) to expand access to high-quality TB drugs.

Roll Back Malaria (RBM) initiative aimed at halving the world's malaria burden by 2010.



Prequalification of Manufacturers

Missionpharma guarantees the supply of safe and effective HIV/AIDS, TB and malaria products by working exclusively with prequalified manufacturers.

“The performance of manufacturers is continuously evaluated and periodic inspections are carried out to ensure maintenance of standards.”

Don't worry ...

In addition to supplying products from WHO prequalified manufacturers, Missionpharma runs its own comprehensive prequalification system, which further allows us to respond to the global demand for product diversity.

The prequalification system is managed by our QA/QC team covering audit, registration and quality control divisions.

In order to ensure that only manufacturers meeting our standards are considered as potential suppliers, they are validated based on the following criteria in our prequalification system:

- Valid manufacturer's license and GMP certificate according to WHO guidelines.
- Assessment of Site Master File.
- Evaluation of product dossiers including conducted bioequivalence studies.
- Performing a formalised GMP audit at the manufacturing site.
- Verification of quality control procedures and source of API (Active Pharmaceutical Ingredient).


... we care

Furthermore, Missionpharma has devised a quality control system verifying that the product quality of each consignment satisfies our standards. This system includes:

- Inspection of the actual product.
- Comparison of Certificates of Analysis against finished product and API specifications.

To supplement our quality control system, we have a network of qualified independent laboratories undertaking further analysis of the product quality when required.

In case of product complaint or recall, the situation is handled strictly according to Standard Operating Procedures (SOPs) to ensure that corrective and preventive actions are taken in each case.



Purchase Competences

Our professional team of purchasers is geared to meet customers' requirements and patients' needs for readily available and affordable HIV/AIDS, TB and malaria products.



Sourcing more than a price

Comprehensive experience in sourcing the right product at the right price combined with the large volume discounts obtained from prequalified manufacturers guarantees continued product availability at affordable prices.

Supplying the product at the right price is essential, but a range of additional considerations are also catered for. Our Purchase Department continually evaluates each manufacturer's additional competences, and the following factors are considered prior to every purchase:

- Technical product specifications
- Delivery performance
- Production capacity
- Financial viability
- Service reliability

Evaluating compliance

Finally, supervision and evaluation of manufacturers' performance and product compliance are continuously monitored in close co-operation with the QA/QC Department.



"All members of the Purchase Department have their own field of responsibilities and expertise, in which they are regularly trained in order to maintain and further strengthen their knowledge."



Storage and Distribution

Drug shortage is a significant barrier to successful treatment of HIV/AIDS, TB and malaria. Missionpharma's extensive and efficient logistic set-up enables us to professionally distribute HIV/AIDS, TB and malaria products worldwide.

"Missionpharma gives personal attention to all customer demands. We have an extensive experience in composing medical kits and we facilitate easy use of the product at the final destination by adapting to special customer labelling and packing requirements."

Timing is everything

Successful treatment requires continued product availability including a high degree of accuracy in each delivery. To meet these requirements, Missionpharma has invested in two logistics platforms in Denmark and India.

Besides providing continued access to drugs, this geographical dispersion of warehouse facilities diminishes the distance between the manufacturers and final recipients and gives us the capacity to keep delivery time and transportation costs at a minimum.


Avoid stock out

With a storage capacity of 13,000 m² Missionpharma is able to stock large quantities of pharmaceuticals, thereby minimising the risk of stock out. Customers who need extra storage capacity may preposition their products in our warehouses, which will allow them to enjoy uninterrupted access to their products.

Sharing know-how

To ensure maintenance of quality standards, our warehouse personnel in Denmark and India regularly complete extensive training programmes on storage practice as well as safety regulations.

The safe delivery of goods at the final destination is of utmost importance to us. Each member of Missionpharma's Logistics Department is responsible for a particular geographical area and can offer an extensive knowledge and expertise and advice on the most optimal solution for each delivery.



HIV/AIDS focus

More than 60 million people have been infected with AIDS worldwide since HIV/AIDS was first reported in 1981, and almost 30 million have already died from AIDS.



Prevention

Missionpharma is expanding the availability and accessibility of condoms, which provide the only effective protection against sexually transmitted HIV virus.

We also encourage the use of single-use injection devices, including AD syringes, which provide an additional opportunity to prevent the dangerous reuse of injection equipment.

Detection and monitoring

Included in our range of products are easy-to-use and cost-effective diagnostic tests as well as prognostic tests to optimise the timing of HIV treatment by monitoring the CD4 level.

Following the recommendations of the WHO Essential Health Technologies Department, Missionpharma also supports and promotes alternative approaches for laboratory monitoring of antiretroviral (ARV) therapy in developing countries. This is backed by our co-operation with partners in the Danish biotech industry.

Treatment

In order to strongly improve access to and affordability of HIV/AIDS-related care and treatment, we offer a full range of HIV/AIDS products from prequalified manufacturers.

Today, Missionpharma India supplies the following ARV agents:

- Non-Nucleoside Reverse Transcriptase Inhibitors
- Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors

Additionally, Missionpharma offers the following HIV/AIDS-related drugs:

- Antibacterial and antimycobacterial agents
- Antiprotozoal agents
- Antiviral agents
- Antifungal agents
- Anti-cancer drugs



“A serious source of infection is the reuse of injection devices causing 5% of all new HIV infections in developing and transitional countries each year. To reduce this tendency, Missionpharma proposes to pack and distribute single use injection devices, single dose diluent and injectable products in a single kit.”*

*Source: Department of Essential Health Technologies, WHO: “Prevention of health care – associated with HIV infection”



focus

Tuberculosis

Though curable, TB causes 2 million deaths per year. Every person with active TB may infect 10 to 15 people annually and it is therefore essential to trace and treat the infectious cases in order to limit the spreading of the disease.

“As recommended by the WHO, Missionpharma promotes the use of 4-drug FDC (150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide and 275 mg ethambutol), which is included in the WHO Model List of Essential Medicines.”

Prevention

A highly contagious disease as TB leaves one with only a few prevention methods. Most effective towards particularly children is the BCG vaccine, which is supplied by Missionpharma from prequalified manufacturers.

Detection


To limit the aggressive spread of TB, early diagnosis is one of the most important parameters. Besides laboratory equipment, easy-to-use rapid TB tests, x-ray films, tuberculin injections, sputum containers and Ziehl-Neelsen stain are the most widely used devices when diagnosing TB. These products are all supplied by Missionpharma.

Treatment

Missionpharma offers all first-line anti-TB products in various strengths and dosage forms and promotes the use of 2-, 3-, 4-drug fixed-dose combinations (FDC).

FDC enjoys many advantages over other drugs, both for the patient and the medical staff. Using FDC simplifies the treatment, so fewer tablets are needed and distribution becomes easier. Furthermore, it is less complicated to calculate the correct dosage and the risk of drug-resistance often seen in monotherapy is reduced. The use of FDC therefore facilitates the implementation of DOTS.

Additionally, Missionpharma offers second-line anti-TB products, which has proven to be an effective and necessary supplement to first-line anti-TB products in areas where multi-drug resistance has developed.



Malaria focus

Malaria causes the death of more than 1 million people annually, mostly children under the age of 5, and the last two decades have seen a dramatic rise in the annual mortality, even if an infected person can be cured in just 3 days.



Prevention

The best prevention against the life-threatening mosquito bites that cause malaria is the use of bednets. Our continued focus on expanding the availability of bednets is of crucial importance, knowing that less than 10% of children in Africa sleep under one.

Reaching further, Missionpharma encourages the use of insecticide-treated bednets as well as long lasting insecticide-treated bednets manufactured according to WHOPES (WHO Pesticide Evaluation Scheme).

Detection

Delayed treatment of malaria may have severe consequences and a proper and early diagnosis is therefore essential. As an alternative to diagnosis based on microscopy, Missionpharma

supplies reliable and easy-to-use diagnostic tests, which provide evidence of the presence of malaria parasites in the blood.

Treatment

Missionpharma supplies all common anti-malarial products in different forms and dosages. Where resistance to first-line drugs like chloroquine has developed, combination therapy provides the most effective treatment.

Missionpharma closely follows surveys and recommendations issued by Roll Back Malaria, the WHO and the MSF in order to provide safe and effective artemisinin-based combination therapy (ACT).



“As a response to the development of drug resistance observed in several countries around the world, Missionpharma offers a wide range of anti-malarial products, including combination blisters, fulfilling the needs of most national anti-malarial treatment policies.”



"Missionpharma's activities go far beyond supplying the essential pharmaceutical products to improve the treatment of HIV/AIDS, TB and malaria. Complete solutions is a keyword to our services, and our performance is always backed by personal commitment and attention to all customer needs."

Expect More

We focus on making HIV/AIDS, TB and malaria products physically and financially available to economically disadvantaged populations all over the world.

A joint effort


Missionpharma recognises the crucial need for a common effort towards the fight against HIV/AIDS, TB and malaria. We are continuously committed to promoting products and solutions that are more adaptive to economically disadvantaged populations, and we closely monitor the national and international initiatives launched to fight the three diseases.

Continued commitment

Our commitment to keeping our position as one of the world's leading suppliers of generic medicine and medical devices comes with a responsibility to be constantly aware of the development within our field. We always make our knowledge and expertise available to you and we strive to meet your requirements at any time. This is why you can expect more from Missionpharma.



For procurement assistance, contact us at focus@missionpharma.com



*Missionpharma wants to be
the preferred provider of
generic medicine and medical devices
for the benefit of economically
disadvantaged populations.*

Missionpharma A/S

Vassingerødvej 9 • DK-3540 Lyngby • Denmark

Tel.: +45 48 16 32 00 • Fax: +45 48 16 32 48

info@missionpharma.com • www.missionpharma.com